Scientists are more circumspect about the EPA's findings, saying further investigation is needed to rule out spray drift. Research done by Charles Sturt University's Asad Asaduzzaman has suggested ...

The Food and Drug Administration (FDA) has expanded its approval of a ketamine-derived nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression.

The FDA’s latest approval of the nasal spray Spravato (esketamine) CIII marks a major shift in how major depressive disorder is managed, allowing people who have tried at least two oral ...